Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Hematology

Genotypes, Syndromes & Multi-Organ Health

At a Glance

In adult-onset autosomal recessive sideroblastic anemia, the specific gene variant helps show whether the condition mainly affects red-blood-cell production or may also involve muscles, heart, immunity, hormones, hearing, vision, or nerves, guiding individualized screening and follow-up.

It is important to understand that “Adult-Onset Autosomal Recessive Sideroblastic Anemia” is not a single uniform disease. Instead, it is an umbrella term for a group of different genetic conditions that share one feature: iron-clogged mitochondria in the red blood cell precursors [1][2].

Because different genes provide instructions for different parts of your body, your specific genetic “barcode” (your genotype) heavily influences whether your symptoms are limited to your blood or if they may affect multiple organ systems [3][4].

Monosyndromic vs. Syndromic Disease

When you receive your genetic test results, your doctor will look for which specific gene is affected. This helps categorize your condition into one of two broad groups:

1. Monosyndromic (Blood-Focused)

In these cases, the genetic defect primarily impacts the production of red blood cells. A common recessive example is a mutation in the SLC25A38 gene [1]. While this often causes severe anemia in childhood, some adults are diagnosed later if their specific mutation allows the body to compensate for a longer period [2]. For these patients, the primary medical concerns are managing anemia and preventing iron overload [5].

2. Syndromic (Multi-System)

Other genetic mutations affect mitochondrial “housekeeping” tasks that many cells in your body need to perform, such as protein building or energy production [6]. In these syndromic forms, the anemia is just one part of a larger clinical picture. Common syndromes include:

  • MLASA (Myopathy, Lactic Acidosis, and Sideroblastic Anemia): Associated with YARS2 or PUS1 genes, this syndrome may affect the muscles, heart, and the blood [3][7].
  • SIFD (Sideroblastic Anemia, Immunodeficiency, Fevers, and Developmental Delay): Associated with the TRNT1 gene, this can involve the immune system and inflammatory responses [4].
  • Perrault Syndrome: Associated with genes like LARS2, this can involve hearing loss and, in females, early ovarian failure [8].

Extrahematologic Features: What to Watch For

If you have a syndromic genotype, your care team may need to look beyond your blood counts. Depending on your gene, your condition may be associated with the following (though not every person will develop every symptom):

System Potential Symptoms & Features Genes Often Associated
Muscles Myopathy (muscle weakness), extreme exercise intolerance, and lactic acidosis (a buildup of acid in the blood after activity). [3][7] YARS2, PUS1
Heart Cardiomyopathy (weakening of the heart muscle) or abnormal heart rhythms. [3] YARS2, PUS1, TRNT1
Immune System Frequent infections, periodic fevers, or low levels of protective antibodies. [4][9] TRNT1
Endocrine Insulin-dependent diabetes or thyroid issues. [10][9] PUS1, TRNT1
Neurological Hearing loss, vision changes, or nerve pain (neuropathy). [8][11] LARS2, GLRX5

Why Your Genotype Matters

Knowing your specific mutation is critical because it acts as a roadmap for your future care. For example:

  • Targeted Screening: If you have a YARS2 variant, your doctor may recommend baseline heart ultrasounds (echocardiograms) and lung function tests, because heart and respiratory weakness can develop gradually [3].
  • Pregnancy Planning: Some genotypes (like YARS2) carry specific risks for cardiorespiratory complications during and after pregnancy, requiring close coordination with high-risk maternal-fetal medicine specialists [12].
  • Infection Prevention: For those with TRNT1 mutations, protecting the immune system is vital. An immunologist should individualize your vaccine schedule and evaluate whether therapies like immunoglobulin replacement are clinically indicated [13].

By identifying the exact genetic cause, you and your doctors can move from “wait and see” to a proactive, individualized baseline assessment that protects your whole body.

Common questions in this guide

What is the difference between blood-focused and syndromic sideroblastic anemia?
A blood-focused, or monosyndromic, form mainly affects red blood cell production, so care centers on anemia and excess iron. A syndromic form can also affect organs such as the muscles, heart, immune system, hormone-producing organs, hearing, vision, or nerves. The gene involved helps distinguish these patterns.
What symptoms outside the blood should I watch for?
Depending on the gene, possible warning signs include muscle weakness, poor exercise tolerance, breathing problems, heart rhythm changes, repeated infections or fevers, diabetes or thyroid problems, hearing or vision changes, and numbness or nerve pain. Not everyone with a syndromic form develops all of these features, so new or worsening symptoms should be discussed with the care team.
What screening may be needed with a YARS2 variant?
A doctor may recommend a baseline echocardiogram, which is an ultrasound of the heart, and pulmonary function tests that measure breathing. These tests can identify heart or respiratory muscle weakness that may develop gradually, even if you are not short of breath.
How does a TRNT1 variant affect infection prevention?
TRNT1-related disease can be associated with repeated infections, periodic fevers, or low levels of protective antibodies. An immunologist can tailor vaccines and immune monitoring and decide whether immunoglobulin replacement is appropriate.
Does the genetic result matter for pregnancy planning?
Yes. Some genotypes, including YARS2-related disease, may raise the risk of heart or breathing complications during or after pregnancy, so planning should involve the hematology or genetics team and a high-risk maternal-fetal medicine specialist.
Why is it important to identify the exact gene?
The gene result can show whether the condition is mainly limited to blood production or may involve several organ systems. It helps clinicians choose baseline heart, lung, immune, and other organ checks and plan follow-up tailored to your risks.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my genetic test results, do I have a 'monosyndromic' or a 'syndromic' form of sideroblastic anemia?
  2. 2.Should I have a baseline echocardiogram (heart ultrasound) or pulmonary function test even if I don't feel short of breath?
  3. 3.Are there specific 'red flag' symptoms like muscle pain or exercise intolerance that I should report immediately for my specific genotype?
  4. 4.Does my genetic variant put me at a higher risk for developing diabetes or hearing loss later in life?
  5. 5.Given my genotype, should I see an immunologist to discuss whether I need specific vaccines or immune monitoring?
  6. 6.How often should we monitor my blood lactate levels and organ function (liver, kidney, heart)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Clinical characterization and hematopoietic stem cell transplant outcomes for congenital sideroblastic anemia caused by a novel pathogenic variant in SLC25A38.

    Uminski K, Houston DS, Hartley JN, et al.

    Pediatric blood & cancer 2020; (67(10)):e28623 doi:10.1002/pbc.28623.

    PMID: 32790119
  2. 2

    Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.

    Cazzola M, Malcovati L

    Hematology. American Society of Hematology. Education Program 2015; (2015()):19-25 doi:10.1182/asheducation-2015.1.19.

    PMID: 26637696
  3. 3

    Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.

    Sommerville EW, Ng YS, Alston CL, et al.

    JAMA neurology 2017; (74(6)):686-694 doi:10.1001/jamaneurol.2016.4357.

    PMID: 28395030
  4. 4

    Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).

    Li Y, Deng M, Han T, et al.

    Journal of clinical immunology 2023; (43(4)):780-793 doi:10.1007/s10875-023-01441-7.

    PMID: 36729249
  5. 5

    Pathophysiology and classification of iron overload diseases; update 2018.

    Brissot P, Troadec MB, Loréal O, Brissot E

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2019; (26(1)):80-88 doi:10.1016/j.tracli.2018.08.006.

    PMID: 30173950
  6. 6

    Ubiquitously Expressed Proteins and Restricted Phenotypes: Exploring Cell-Specific Sensitivities to Impaired tRNA Charging.

    Kuo ME, Antonellis A

    Trends in genetics : TIG 2020; (36(2)):105-117 doi:10.1016/j.tig.2019.11.007.

    PMID: 31839378
  7. 7

    Myopathy, lactic acidosis and sideroblastic anemia 1 (MLASA1): A 25-year follow-up.

    Woods J, Cederbaum S

    Molecular genetics and metabolism reports 2019; (21()):100517 doi:10.1016/j.ymgmr.2019.100517.

    PMID: 31641589
  8. 8

    The expanding LARS2 phenotypic spectrum: HLASA, Perrault syndrome with leukodystrophy, and mitochondrial myopathy.

    Riley LG, Rudinger-Thirion J, Frugier M, et al.

    Human mutation 2020; (41(8)):1425-1434 doi:10.1002/humu.24050.

    PMID: 32442335
  9. 9

    A phenotypic expansion of TRNT1 associated sideroblastic anemia with immunodeficiency, fevers, and developmental delay.

    Odom J, Amin H, Gijavanekar C, et al.

    American journal of medical genetics. Part A 2022; (188(1)):259-268 doi:10.1002/ajmg.a.62482.

    PMID: 34510712
  10. 10

    Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations.

    Cao M, Donà M, Valentino ML, et al.

    Neurogenetics 2016; (17(1)):65-70 doi:10.1007/s10048-015-0465-x.

    PMID: 26556812
  11. 11

    GLRX5-associated [Fe-S] cluster biogenesis disorder: further characterisation of the neurological phenotype and long-term outcome.

    Sankaran BP, Gupta S, Tchan M, et al.

    Orphanet journal of rare diseases 2021; (16(1)):465 doi:10.1186/s13023-021-02073-z.

    PMID: 34732213
  12. 12

    Decompensation of cardiorespiratory function and emergence of anemia during pregnancy in a case of mitochondrial myopathy, lactic acidosis, and sideroblastic anemia 2 with compound heterozygous YARS2 pathogenic variants.

    Rudaks LI, Watson E, Oboudiyat C, et al.

    American journal of medical genetics. Part A 2022; (188(7)):2226-2230 doi:10.1002/ajmg.a.62755.

    PMID: 35393742
  13. 13

    Expanding the spectrum of Sideroblastic Anemia with B-cell Immunodeficiency, Periodic Fever and Developmental Delay (SIFD) syndrome: a case report with new clinical insights and novel genetic variant.

    Delle Cave F, Taietti I, Agostini A, et al.

    Frontiers in immunology 2026; (17()):1876025 doi:10.3389/fimmu.2026.1876025.

    PMID: 42688123

This page is for informational purposes only and does not constitute medical advice. Your hematology and genetics team can interpret your genotype and recommend appropriate organ screening and follow-up.

Get notified when new evidence is published on Adult-onset autosomal recessive sideroblastic anemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.